• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Apexigen Inc. (Amendment)

    1/26/23 4:07:41 PM ET
    $APGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APGN alert in real time by email
    SC 13G/A 1 p23-0167sc13ga.htm APEXIGEN, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     

    Apexigen, Inc. (f/k/a Brookline Capital Acquisition Corp.)

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    0375B102

    (CUSIP Number)
     

    December 31, 2022

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 0375B10213G/APage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Kepos Capital LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    - 0 -

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IA, PN

             

     

     

     

    CUSIP No. 0375B10213G/APage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Mark Carhart

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    - 0 -

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

    CUSIP No. 0375B10213G/APage 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Apexigen, Inc., (f/k/a Brookline Capital Acquisition Corp.) (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 75 Shoreway Road, Suiter C, San Carlos, CA 94070.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:
       
      (i)

    Kepos Capital LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to certain funds and accounts (the "Kepos Funds"), with respect to the Common Stock (as defined in Item 2(d) below) directly held by the Kepos Funds; and

     

      (ii) Mr. Mark Carhart ("Mr. Carhart"), the managing member of Kepos Capital GP LLC, the general partner of the Investment Manager, with respect to the Common Stock directly held by the Kepos Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 11 Times Square, 35th Floor, New York, New York 10036.

     

    Item 2(c). CITIZENSHIP:

     

      The Investment Manager is a Delaware limited partnership.  Mr. Carhart is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the "Common Stock").

     

     

     

    CUSIP No. 0375B10213G/APage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      11374E104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: _______________________________________

     

    Item 4. OWNERSHIP.

     

        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [x]

     

     

     

    CUSIP No. 0375B10213G/APage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.   

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 0375B10213G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: January 26, 2023

     

     

    KEPOS CAPITAL LP
         
         
    By: /s/ Simon Raykher  
    Name: Simon Raykher  
    Title: General Counsel  
         
         
    /s/ Mark Carhart  
    MARK CARHART  
         

     

     

     

     

     

     

     

    Get the next $APGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifshitz Law PLLC Announces Investigations of APGN, GNL, RTL, and BACK

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of APGN and Pyxis Oncology, Inc. Under the terms of the proposed merger, APGN shareholders will receive 0.1725 shares of Pyxis Oncology, Inc. common stock for each share of APGN common stock owned. Following the merger, pre-merger Apexigen shareholders are expected to own approximately 10% of the outstanding equity of the combined company. If you are an APGN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz

      6/3/23 8:17:00 PM ET
      $APGN
      $BACK
      $GNL
      $RTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
      Real Estate Investment Trusts
    • Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

      - Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) - - DDLPS expansion cohort enrolling to inform a potential Phase 3 registration trial - SAN CARLOS, Calif., June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab (sotiga), Ap

      6/3/23 8:00:00 AM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology to Acquire Apexigen

      Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. ("Pyx

      5/24/23 6:45:00 AM ET
      $APGN
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Zabrowksi Dan

      4 - Apexigen, Inc. (0001814140) (Issuer)

      8/25/23 7:42:15 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Wertheimer Samuel P returned 146,383 shares to the company, closing all direct ownership in the company

      4 - Apexigen, Inc. (0001814140) (Issuer)

      8/25/23 7:39:47 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Smith Scott Andrew

      4 - Apexigen, Inc. (0001814140) (Issuer)

      8/25/23 7:37:02 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APGN
    Financials

    Live finance-specific insights

    See more
    • Pyxis Oncology to Acquire Apexigen

      Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. ("Pyx

      5/24/23 6:45:00 AM ET
      $APGN
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma

      -Patients with liposarcoma (LPS) demonstrated prolonged median PFS (mPFS) relative to historical controls treated with standard of care of doxorubicin- -Encouraging PFS data from the ongoing investigator sponsored trial in collaboration with Columbia University supports expansion of the LPS cohort to inform a potential phase 3 registration-enabling trial- -Apexigen to host investor call with sarcoma expert and principal investigator, Gary Schwartz, M.D. at Columbia University, today, November 14, at 8:00 a.m. ET- SAN CARLOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeu

      11/14/22 7:00:00 AM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APGN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Apexigen Inc.

      15-12G - Apexigen, Inc. (0001814140) (Filer)

      9/5/23 4:57:27 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Apexigen Inc.

      S-8 POS - Apexigen, Inc. (0001814140) (Filer)

      8/23/23 5:15:36 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apexigen Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Apexigen, Inc. (0001814140) (Filer)

      8/23/23 9:01:17 AM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Apexigen Inc. (Amendment)

      SC 13G/A - Apexigen, Inc. (0001814140) (Subject)

      2/13/23 4:10:55 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Apexigen Inc.

      SC 13G - Apexigen, Inc. (0001814140) (Subject)

      2/13/23 4:04:53 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apexigen Inc. (Amendment)

      SC 13G/A - Apexigen, Inc. (0001814140) (Subject)

      1/26/23 4:07:41 PM ET
      $APGN
      Biotechnology: Pharmaceutical Preparations
      Health Care